Loading...
XNASRZLT
Market cap301mUSD
Jan 08, Last price  
5.21USD
1D
-4.05%
1Q
11.56%
IPO
-74.59%
Name

Rezolute Inc

Chart & Performance

D1W1MN
XNAS:RZLT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
96.04%
Rev. gr., 5y
%
Revenues
0k
Net income
-68m
L+32.19%
-49,287-6,727,457-9,730,454-11,362,364-14,935,542-20,277,132-29,861,776-30,417,000-20,333,000-21,277,000-38,781,000-51,787,000-68,459,000
CFO
-57m
L+28.97%
-40,398-1,627,965-3,167,357-7,078,894-10,488,498-13,311,459-14,113,080-15,304,000-24,168,000-20,441,000-39,616,000-44,481,000-57,368,000
Earnings
Feb 11, 2025

Profile

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
URL
https://www.rezolutebio.com/
IPO date
Dec 23, 2011
Employees
47
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
70,423
56,372
42,099
Unusual Expense (Income)
NOPBT
(70,423)
(56,372)
(42,099)
NOPBT Margin
Operating Taxes
(138)
(2,279)
Tax Rate
NOPAT
(70,423)
(56,234)
(39,820)
Net income
(68,459)
32.19%
(51,787)
33.54%
(38,781)
82.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
49,017
12,330
112,037
BB yield
-22.15%
-12.17%
-178.00%
Debt
Debt current
568
541
108
Long-term debt
3,888
4,415
268
Deferred revenue
Other long-term liabilities
468
412
407
Net debt
(122,681)
(113,410)
(150,034)
Cash flow
Cash from operating activities
(57,368)
(44,481)
(39,616)
CAPEX
(153)
Cash from investing activities
48,699
(101,464)
Cash from financing activities
63,029
11,571
148,979
FCF
(70,213)
(58,259)
(39,563)
Balance
Cash
126,874
101,896
150,410
Long term investments
263
16,470
Excess cash
127,137
118,366
150,410
Stockholders' equity
(329,470)
(261,299)
(209,164)
Invested Capital
453,169
380,361
359,230
ROIC
ROCE
EV
Common stock shares outstanding
51,465
51,187
19,487
Price
4.30
117.17%
1.98
-38.70%
3.23
-77.37%
Market cap
221,300
118.35%
101,350
61.02%
62,943
-42.50%
EV
98,618
(12,060)
(87,091)
EBITDA
(70,387)
(56,342)
(42,086)
EV/EBITDA
0.21
2.07
Interest
1,807
Interest/NOPBT